Clinical Trial Results:
            Induction of Tolerance with Immunoablation and 
Autologous Hematopoietic Stem Cell Transplantation (ASCT) for 
Severe Systemic Lupus Erythematosus (SLE) Refractory to 
Standard Immunosuppressive Therapy 
AN OPEN-LABEL, CONTROLLED, PHASE II MULTICENTER TRIAL OF IMMUNOABLATIVE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND ANTI-THYMOCYTE GLOBULIN AND TRANSPLANTATION OF PURIFIED CD34+ AUTOLOGOUS HEMAPOIETIC STEM CELLS VERSUS CURRENTLY AVAILABLE IMMUNOSUPPRESSIVE THERAPY FOR THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS.
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2006-001269-40 | 
    Trial protocol  | 
        DE | 
    Global completion date  | 
        |
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        |
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        |
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        |
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    30 Oct 2025
                             
         | 
    
    First version publication date  | 
        
                                    30 Oct 2025
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                p.e..statement | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.